Adrian B McDermott
Affiliation: National Institutes of Health
- CD8(+) T cells in preventing HIV infection and diseaseAdrian B McDermott
Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
AIDS 26:1281-92. 2012..In the context of previous clinical HIV/AIDS vaccine trials, we consider the challenges faced by therapeutic and vaccine strategies designed to elicit effective HIV-specific CD8 T cells...
- HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infectionRebecca M Lynch
Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
Curr Opin HIV AIDS 8:288-94. 2013....
- Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infectionTakuya Yamamoto
Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA
J Virol 86:5877-84. 2012..The ability to elicit such virus-specific EM CD8(+) T cells might contribute substantially to an efficacious HIV/AIDS vaccine, even after breakthrough infection...
- Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trialUzma N Sarwar
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
PLoS ONE 9:e106240. 2014..Needle-free delivery improves the immunogenicity of DNA vaccines but is also associated with more local reactogenicity. Here we report the first comparison of Biojector and needle administration of a candidate rAd5 HIV vaccine...